- Home
- PRGS vs GERN Comparison
PRGS vs GERN Comparison
Compare PRGS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- GERN
- Stock Information
- Founded
- PRGS 1981
- GERN 1990
- Country
- PRGS United States
- GERN United States
- Employees
- PRGS N/A
- GERN N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- PRGS Technology
- GERN Health Care
- Exchange
- PRGS Nasdaq
- GERN Nasdaq
- Market Cap
- PRGS 2.8B
- GERN 2.5B
- IPO Year
- PRGS 1991
- GERN 1996
- Fundamental
- Price
- PRGS $62.94
- GERN $2.89
- Analyst Decision
- PRGS Buy
- GERN Strong Buy
- Analyst Count
- PRGS 8
- GERN 10
- Target Price
- PRGS $71.50
- GERN $7.15
- AVG Volume (30 Days)
- PRGS 545.8K
- GERN 14.8M
- Earning Date
- PRGS 01-21-2025
- GERN 02-26-2025
- Dividend Yield
- PRGS 0.83%
- GERN N/A
- EPS Growth
- PRGS 5.04
- GERN N/A
- EPS
- PRGS 1.86
- GERN N/A
- Revenue
- PRGS $715,418,000.00
- GERN $29,480,000.00
- Revenue This Year
- PRGS $10.13
- GERN $31,478.06
- Revenue Next Year
- PRGS $22.59
- GERN $290.89
- P/E Ratio
- PRGS $33.87
- GERN N/A
- Revenue Growth
- PRGS 6.05
- GERN 9199.68
- 52 Week Low
- PRGS $48.00
- GERN $1.64
- 52 Week High
- PRGS $70.56
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- PRGS 37.32
- GERN 25.84
- Support Level
- PRGS $61.76
- GERN $2.80
- Resistance Level
- PRGS $65.60
- GERN $3.68
- Average True Range (ATR)
- PRGS 1.09
- GERN 0.18
- MACD
- PRGS -0.12
- GERN -0.04
- Stochastic Oscillator
- PRGS 24.58
- GERN 10.23
About PRGS Progress Software Corporation (DE)
Progress Software Corporation is a provider of cloud-based security solutions to large-and mid-sized organizations in a wide range of industries. Its product includes OpenEdge; Chef; Developer Tools; Kemp LoadMaster; MOVEit; DataDirect; WhatsUp Gold; Sitefinity; Flowmon and Corticon. The company derives revenue from perpetual licenses to its products, but some products also use term licensing models. Its cloud-based offerings use a subscription-based model. A majority of the firm's revenue is generated in the United States and it also has presence in Canada, the Middle East, and Africa (EMEA), Latin America, and Asia Pacific.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.